ENDP - Endo International plc

NasdaqGS - NasdaqGS Delayed price. Currency in USD
7.54
+0.24 (+3.29%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close7.30
Open7.32
Bid7.41 x 800
Ask7.70 x 4900
Day's range7.16 - 7.65
52-week range5.77 - 17.99
Volume5,322,351
Avg. volume6,280,804
Market cap1.68B
Beta-0.32
PE ratio (TTM)N/A
EPS (TTM)-23.00
Earnings date6 Nov 2017 - 10 Nov 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.31
Trade prices are not sourced from all markets
  • Market Realist2 days ago

    Inside Endo’s Measures to Boost Margins

    With only a handful of buyers controlling a majority of the market, Endo's products are facing price cuts.

  • Market Realist2 days ago

    Inside Endo’s Branded Pharma and International Segments

    Lidoderm, Opana ER, and Percocet are Endo's top pain management drugs, contributing revenues of ~$88 million, ~$159 million and ~$139 million, respectively.

  • Market Realist2 days ago

    Inside Endo’s Key Business Segments

    In 2016 and 2015, Endo's US Generic segment contributed 64% and 51% of total revenues, respectively. The US Branded segment contributed 29% and 39.

  • Market Realist2 days ago

    Endo on the Street: Analyst Recommendations in November

    Of the 21 analysts covering Endo in November 2017, six recommend a “buy” for the stock, while 14 recommend a "hold," and one recommends a "sell."

  • Reuters - UK Focus3 days ago

    Endo unit cleared of liability in first testosterone replacement trial

    A federal jury in Chicago said on Thursday that Endo International (NasdaqGS: ENDP - news) 's Auxilium unit was not responsible for the heart attack a man suffered while using the company's testosterone replacement drug Testim. The verdict was a victory for the drugmaker in its first trial over allegations it defectively designed Testim, a skin gel, and negligently misrepresented its risks. Matthew Maletta, Endo's chief legal officer, said in a statement that Testim was safe and Endo would continue to vigorously defend against similar claims.

  • Business Wire3 days ago

    ENDO INTERNATIONAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Endo International, Plc to Contact the Firm

    Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Endo International, Plc. .

  • Associated Press9 days ago

    Endo reports 3Q loss

    On a per-share basis, the Dublin-based company said it had a loss of 43 cents. Earnings, adjusted for one-time gains and costs, were 91 cents per share. The results topped Wall Street expectations. The ...

  • Implied Volatility Surging for Endo (ENDP) Stock Options
    Zacks10 days ago

    Implied Volatility Surging for Endo (ENDP) Stock Options

    Endo (ENDP) needs investors to pay close attention to the stock based on moves in the options market lately.

  • The Wall Street Journal12 days ago

    [$$] Kentucky Is Latest State to Sue an Opioid-Painkiller Maker

    Kentucky joins the roster of states and communities suing opioid makers, this time focused on Endo and its withdrawn painkiller Opana ER.

  • Why Endo International plc Jumped and Then Faded -- Twice
    Motley Fool19 days ago

    Why Endo International plc Jumped and Then Faded -- Twice

    The drugmaker can't sustain a rally despite solid third quarter preliminary results.

  • Barrons.com20 days ago

    Endo's Upbeat Earnings: Don't Get Too Excited

    Endo International (ENDP) is surging Monday morning, after forecasting higher-than-expected third-quarter earnings. Endo pre-announced third quarter earnings per share of 85 cents, 19 cents above consensus, and while it maintained its 2017 EBITDA and EPS guidance, it now expects adjusted EBITDA from continuing operations and adjusted diluted EPS from continuing operations to be at the upper end of its 2017 financial guidance ranges. The shares, which have tumbled nearly 62% year to date, jumped on the news, but Cantor Fitzgerald's Louise Chen and her team warn investors shouldn't get too excited.

  • Here's Why Endo International Stock Dropped as Much as 13.8% Today
    Motley Fool23 days ago

    Here's Why Endo International Stock Dropped as Much as 13.8% Today

    The generic pharmaceutical leader is suing the Food and Drug Administration -- and it might be right. Then again, it might not matter.

  • Reuterslast month

    Amneal, Impax combine to tackle generic drug pricing pressure

    The deal comes at a time when speedy approvals of generics by U.S. regulators have ratcheted up competition in the sector, mounting pressure on smaller drugmakers such as Impax, which has a market cap of about $1.48 billion (£1.1 billion). Adding to the woes of generics makers, U.S. retail pharmacies including Wal-Mart Stores Inc (WMT.N) and Walgreens Boots Alliance Inc (WBA.O) are wielding more leverage when buying such drugs, leading to continued price erosion.

  • MarketWatchlast month

    Omeros shares surge 10% after settlement with Endo delays generic to 2032

    Omeros Corporation shares surged as much as 10% in morning trade Thursday, before paring some gains, after the company announced a settlement with Endo International PLC's Par Pharmaceutical Inc. that ...

  • Barrons.com2 months ago

    Debt Worries Outweigh Specialty Pharma Pipeline Potential

    BMO Capital Markets' Gary Nachman and his team recently hosted an event with executives from Valeant Pharmaceuticals (VRX), Impax Laboratories (IPXL) and Endo International (ENDP), as they try to navigate a "challenging time in specialty pharma." Nachman writes that all three companies have a high amount of leverage, but they're taking different approaches: While Valeant and Endo are taking a more long-term approach of addressing concerns about their debt by executing their main businesses, Impax appears to be planning a "creative transaction" in the near-term that Nachman writes could "potentially transform the company," while also delevering its balance sheet.

  • Barrons.com2 months ago

    Morning Movers: Endo Slumps, Hain Jumps, Philip Morris Rises

    Stocks look set for a lower open today as Trump's tax plan continues to dominate the news. S&P 500 futures have declined 0.2%, while Dow Jones Industrial Average futures have fallen 0.2%. Nasdaq Composite ...

  • Reuters - UK Focus2 months ago

    Indivior settles addiction treatment case with Mylan for undisclosed terms

    Indivior's U.S. subsidiary, together with Monosol Rx, has settled a patent dispute with U.S. drugmaker Mylan related to generic versions of its opioid addiction treatment Suboxone, which generates 80 percent ...

  • Reuters - UK Focus2 months ago

    Indivior files lawsuits against Suboxone generic rivals

    Indivior (Frankfurt: 2IVA.F - news) 's U.S. subsidiary has filed lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone, which generates 80 percent of the drugmaker's revenue. The patent lawsuits were filed against Dr. Reddy's , Allergan Plc (Frankfurt: A1W5NE - news) 's Actavis Laboratories, Endo International's Par Pharmaceutical, Alvogen Pharma US, Teva Pharmaceutical Industries and Mylan NV.

  • Reuters - UK Focus2 months ago

    Indivior files patent lawsuits against generic Suboxone rivals

    Indivior said on Friday its U.S. subsidiary has filed patent lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone, which generates 80 percent of Indivior's ...

  • After-hours buzz: ENDP, ASNA & more
    CNBC5 months ago

    After-hours buzz: ENDP, ASNA & more

    See which stocks are posting big moves after the bell.

  • Reuters - UK Focus6 months ago

    US STOCKS-Wall Street loses oomph but Apple crosses $800-billion mark

    The S&P 500 fell on Tuesday after edging up to an intra-day record high for the second straight session, while Apple became the first U.S. company to close with a market capitalization above $800 billion. Better-than-expected quarterly earnings from U.S. companies and Emmanuel Macron's victory in the French presidential election on Sunday have given investors confidence, but valuations for U.s. stocks are already higher than average. The hope that U.S. President Donald Trump will cut corporate and personal taxes remained in focus for investors.

  • Reuters - UK Focus6 months ago

    US STOCKS-Wall Street loses steam after S&P 500 touches record

    The S&P 500 slipped marginally on Tuesday after edging up to an intra-day record high for the second straight session, with a rise in Marriott International (Frankfurt: 913070 - news) and other consumer discretionary shares offsetting falling energy shares. Better-than-expected quarterly earnings from U.S. companies and Emmanuel Macron's victory in the French presidential election on Sunday have given investors confidence, but valuations for U.s. stocks are already higher than average.

  • Cramer Remix: My advice for Trump's tweets and Mexico
    CNBC10 months ago

    Cramer Remix: My advice for Trump's tweets and Mexico

    Jim Cramer offered his take on the dollar-peso debacle and how President-Elect Donald Trump should adjust his tweeting strategy.

  • Cramer's biggest winner and loser of the S&P for 2017
    CNBC10 months ago

    Cramer's biggest winner and loser of the S&P for 2017

    Jim Cramer reviews the stocks of the S&P 500 to find out of they could run out of fuel in the new year.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes